8-K: Gossamer Bio Reports Q4/FY25 Results, Seralutinib Misses Primary Endpoint

Gossamer Bio announced its fourth quarter and full-year 2025 financial results, alongside topline Phase 3 PROSERA study results for seralutinib which narrowly missed its primary endpoint.

Summary

• Seralutinib's Phase 3 PROSERA study for pulmonary arterial hypertension (PAH) narrowly missed its primary endpoint, showing a placebo-adjusted improvement in six-minute walk distance (6MWD) of +13.3 meters (p = 0.0320) against a prespecified statistical alpha threshold of 0.025.
• Despite missing the primary endpoint, management believes the totality of evidence supports seralutinib as an active drug, with more pronounced effects observed in intermediateand high-risk PAH patients (+20.0 meters, nominal p = 0.0207).
• Key secondary endpoints, including NT-proBNP (location shift of approximately -120.4 ng/L, nominal p = 0.0002), favored seralutinib across the overall population and in specific subgroups like connective tissue disease-associated pulmonary arterial hypertension (CTDPAH) (+37 meters 6MWD, nominal p = 0.0104).
• Enrollment in the Phase 3 SERANATA Study in pulmonary hypertension associated with interstitial lung disease (PH-ILD) has been paused while the company evaluates the implications of PROSERA results and engages with regulators.
• The company implemented a reduction in force and other cost-containment measures to better align resources with near-term priorities.
• Cash, cash equivalents, and marketable securities totaled $136.9 million at year-end 2025, with an expected cash runway into the first quarter of 2027.
• Net loss for the full year 2025 significantly increased to $170.4 million ($0.75 per share) from $56.5 million ($0.25 per share) in 2024.
• Total revenue decreased to $48.471 million in 2025 from $114.701 million in 2024, primarily due to the absence of significant license sale revenue in 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development due to the primary endpoint miss in a pivotal Phase 3 trial, leading to uncertainty for seralutinib's future and necessitating a workforce reduction and strategic re-evaluation.

Positives

• Seralutinib demonstrated positive trends in key secondary endpoints and specific subgroups (intermediate/high-risk PAH, CTDPAH) despite narrowly missing the primary endpoint, suggesting potential efficacy in certain patient populations.
• Cash, cash equivalents, and marketable securities of $136.9 million at year-end 2025 are expected to fund operations into the first quarter of 2027, providing a runway for strategic evaluation.
• Implementation of a reduction in force and cost-containment measures indicates proactive management of resources in response to clinical trial results and financial performance.

Negatives

• The Phase 3 PROSERA study for seralutinib in PAH narrowly missed its prespecified statistical threshold for the primary endpoint (p=0.0320 vs. 0.025).
• Enrollment in the Phase 3 SERANATA Study for PH-ILD has been paused, indicating uncertainty regarding the development path for seralutinib in this indication.
• Net loss for the full year 2025 significantly widened to $170.4 million from $56.5 million in 2024.
• Total revenue decreased substantially from $114.701 million in 2024 to $48.471 million in 2025.
• Total stockholders' equity shifted from a positive $29.492 million at year-end 2024 to a deficit of $(122.760) million at year-end 2025.
• A reduction in force was implemented as part of cost-containment measures, indicating a need to scale back operations.

Risks

• Topline results reported are based on preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review.
• The company may not be able to identify a development path forward for seralutinib, whether as a result of FDA feedback or otherwise, and any path forward may require additional capital and other resources, which may not be available on reasonable terms, if at all, or may limit the commercial opportunity.
• The company may need to further evaluate its current workforce in light of potential development paths for seralutinib.
• Potential delays in the commencement, enrollment, and completion of clinical trials.
• Comparative safety information is not based on a head-to-head comparison, and differences exist between study designs and subject characteristics which could confound the results.
• Dependence on third parties in connection with product manufacturing, research, and preclinical and clinical testing.
• Results of preclinical studies and early clinical trials with seralutinib are not necessarily predictive of future results.
• The success of any future clinical trials and preclinical studies for seralutinib is not guaranteed.
• Regulatory developments in the United States and foreign countries could impact development and approval.
• Unexpected adverse side effects or inadequate efficacy of seralutinib may limit its development, regulatory approval, and/or commercialization, or may result in clinical holds, recalls, or product liability claims.
• Inability to obtain and maintain intellectual property protection for seralutinib.
• Inability to comply with obligations in collaboration agreements with third parties or agreements under which intellectual property rights are licensed.
• Capital resources may be used sooner than expected.

Future Outlook

The company plans to conduct additional analyses of the PROSERA dataset and request a Type C meeting with the FDA, potentially in June 2026, to discuss the data and potential regulatory paths forward for seralutinib in PAH. Enrollment in the Phase 3 SERANATA Study for PH-ILD is paused while evaluating PROSERA implications. The company expects its current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2027.

Management Comments

• "Following our PROSERA topline results, we are focused on fully understanding the PROSERA dataset, engaging with the FDA, and evaluating strategic options and capital allocation to position the Company for the future." Faheem Hasnain, Chairman, Co-Founder and CEO.
• "PROSERA narrowly missed the prespecified statistical threshold for its primary endpoint; however, we believe the totality of evidence supports that seralutinib is an active drug in PAH, with the most pronounced effects observed in patients with more advanced disease." Faheem Hasnain, Chairman, Co-Founder and CEO.

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry, particularly in rare diseases like PAH and PH-ILD, is highly sensitive to clinical trial outcomes. A narrow miss on a primary endpoint, even with positive secondary data, often leads to significant market uncertainty and necessitates careful regulatory navigation. The pause in the SERANATA study reflects the broader industry practice of re-evaluating development strategies in light of new clinical data, especially when resources are constrained.

Comparison to Industry Standards

• The primary endpoint miss for seralutinib's 6MWD improvement (+13.3 meters, p=0.0320) against a 0.025 alpha threshold is a critical setback, as regulatory approval often hinges on meeting prespecified statistical significance.
• However, the observed +20.0 meters 6MWD improvement in the intermediateand high-risk subgroup (nominal p=0.0207) and +37 meters in the CTDPAH subgroup (nominal p=0.0104) suggests potential efficacy in specific patient populations, which could be a basis for discussions with the FDA.
• For context, other PAH treatments have shown varying 6MWD improvements in their pivotal trials; for example, selexipag (Uptravi) showed a 4.2-meter placebo-adjusted improvement in 6MWD in its Phase 3 GRIPHON study, but its primary endpoint was time to first morbidity/mortality event. Macitentan (Opsumit) also used a morbidity/mortality endpoint. Treprostinil (Tyvaso) showed a 20-meter improvement in 6MWD in its INCREASE study for PH-ILD. Direct comparison is challenging due to different trial designs and primary endpoints, but the magnitude of improvement in subgroups for seralutinib is notable.
• The significant increase in net loss and decrease in cash position, coupled with a workforce reduction, indicates a challenging financial environment, common for biotechs facing clinical trial setbacks.

Stakeholder Impact

• Shareholders: Negative impact due to the primary endpoint miss, increased net loss, decreased revenue, and uncertainty regarding seralutinib's future, likely leading to share price volatility.
• Employees: Negative impact due to the implemented reduction in force.
• Patients (PAH/PH-ILD): Uncertainty regarding the availability and development timeline of seralutinib as a potential treatment option.
• Chiesi Group (Collaborator): Potential re-evaluation of the global collaboration agreement for seralutinib development.

Next Steps

• Conduct additional analyses of the PROSERA dataset.
• Request a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss PROSERA data and potential regulatory paths forward, potentially in June 2026.
• Evaluate strategic options and capital allocation.
• Continue limited work on RT234 pursuant to its option agreement.
• Engage with regulators on potential paths forward for seralutinib in PH-ILD following the pause of the SERANATA study.

Key Dates

Recommendation

The primary endpoint miss in a pivotal Phase 3 trial for the company's lead asset, seralutinib, is a critical setback that significantly impacts its commercial viability and regulatory path. Despite positive secondary data, the failure to meet the prespecified statistical threshold creates substantial uncertainty. This, combined with a widening net loss, declining revenue, a negative shift in shareholder equity, a workforce reduction, and the pausing of another key clinical trial, indicates severe operational and financial challenges. The stock faces significant downside risk due to these fundamental issues and the high probability of further delays or even discontinuation of development for seralutinib in certain indications.

Keywords

Gossamer Bio, GOSS, Seralutinib, Pulmonary Arterial Hypertension, PAH, PH-ILD, PROSERA, SERANATA, Clinical Trial Results, Biopharmaceutical, Financial Results, Q4 2025, FY 2025, FDA, Drug Development, Workforce Reduction, Cash Runway